ArticleMelanoma management2025
Efficacy and safety of adjuvant systemic therapies in trial non-eligible resected stages III and IV melanoma patients.
Sarah Alsadiq et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it